Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 2000 December 15; 106(12): 1467–1479.
PMCID: PMC387253

Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris–like lesions


Pemphigus is an autoimmune disease of skin adhesion associated with autoantibodies against a number of keratinocyte antigens, such as the adhesion molecules desmoglein (Dsg) 1 and 3 and acetylcholine receptors. The notion that anti-Dsg antibodies alone are responsible for blisters in patients with pemphigus vulgaris (PV) stems from the ability of rDsg1 and rDsg3 to absorb antibodies that cause PV-like skin blisters in neonatal mice. Here, we demonstrate that PV IgGs eluted from rDsg1-Ig-His and rDsg3-Ig-His show similar antigenic profiles, including the 38-, 43-, 115-, and 190-kDa keratinocyte proteins and a non–Dsg 3 130-kDa polypeptide present in keratinocytes from Dsg 3 knockout mouse. We injected into Dsg 3–lacking mice the PV IgGs that did not cross-react with the 160-kDa Dsg 1 or its 45-kDa immunoreactive fragment and that showed no reactivity with recombinant Dsg 1. We used both the Dsg3null mice with a targeted mutation of the Dsg3 gene and the “balding” Dsg3bal/Dsg3bal mice that carry a spontaneous null mutation in Dsg3. These PV IgGs caused gross skin blisters with PV-like suprabasal acantholysis and stained perilesional epidermis in a fishnet-like pattern, indicating that the PV phenotype can be induced without anti–Dsg 3 antibody. The anti–Dsg 1 antibody also was not required, as its presence in PV IgG does not alter the PV-like phenotype in skin organ cultures and because pemphigus foliaceus IgGs produce a distinct phenotype in Dsg3null mice. Therefore, mucocutaneous lesions in PV patients could be caused by non-Dsg antibodies.


In pemphigus vulgaris (PV), blisters develop on oral mucosa. Mucosal lesions are often followed by skin involvement. The deep intraepidermal cleft occurs between the basal cells and the overlaying spinous keratinocytes. In pemphigus foliaceus (PF), the oral mucosa is usually not involved, and cutaneous erosive lesions develop owing to a superficial epidermal split localized to the stratum granulosum. The pathophysiological mechanism causing autoimmune pemphigus is unknown and still being intensively investigated. To date, a catalogue of self-antigens, demonstrated by various authors and detection techniques to react uniquely with pemphigus IgGs, includes approximately 20 molecules with different relative molecular masses, namely: 12, 18, 33, 47, 50, 52, 55, 59, 66, 67, 68, 75, 78, 80, 85, 102, 105, 160, 180, 185/190, and 210 kDa (reviewed in ref. 1). The number of detectable target molecules varies from patient to patient and depends on the sensitivity of the detection technique, i.e., immunoblotting versus immunoprecipitation. Hypothetically, some of these bands may represent degradation products of pemphigus antigens having higher native molecular weights. The number of detectable pemphigus antigens can be substantially reduced by altering the sensitivity of the technique, as is performed when the keratinocyte protein suspension, the source of antigens, is first preabsorbed with normal human serum and then used in an immunoprecipitation assay with PV and PF sera (2, 3). Only a few protein bands remain, including the pairs of 85/130 and 85/160 kDa that were considered to represent the pathophysiologically important targets of PV and PF autoimmunity, respectively (4). Likewise, the number of clones detected in a λgt 11 keratinocyte cDNA library by PV IgG was reduced by substituting the whole PV IgG fraction with the affinity-purified IgG from a single band, the 130-kDa keratinocyte polypeptide (5).

The 130-kDa PV antigen was reported to be a novel keratinocyte desmoglein (Dsg) 3 (5); the 160-kDa PF antigen, Dsg 1 (6); and the 85-kDa antigen, recognized by both PV and PF IgGs, was identified as the adhesion molecule plakoglobin (7). Autoantibodies to these adhesion molecules in pemphigus were interpreted as direct, cause-and-effect pathogenesis with autoantibody binding to an adhesion molecule inducing a disease of skin dyshesion (810). The broad spectrum variety of clinical and histological manifestations of autoimmune pemphigus has been explained by some investigators as an interplay between Dsg 1 and Dsg 3 antibodies. These antibodies are proposed to cause pemphigus directly by disrupting desmosomal junctions within the upper and lower epidermal compartments (11), based on the predominant differential expression of the Dsg1 and Dsg3 genes in the upper and lower epidermis, respectively (12, 13). However, a deletion mutation in the NH2-terminal extracellular domain of Dsg 1 results in the dominantly inherited condition of striate palmoplantar keratoderma without any intraepidermal dyshesion (14). Similar thickening of the stratum corneum without skin blistering also occurs in Dsg 3-truncated transgenic mice (15). Furthermore, no spontaneous gross skin blistering is observed in the Dsg3null mouse with a targeted mutation of the Dsg3 gene or the “balding” Dsg3bal/Dsg3bal mouse with a spontaneous null mutation in the Dsg3 gene (16, 17). Interestingly, even in P-cadherin/Dsg 3 double knockout mice neither spontaneous nor trauma (skin rubbing)–induced gross and microscopic alterations of the integrity of the epidermis can be found (18).

Preabsorption of patients’ sera with recombinant Dsg1-Ig and Dsg3-Ig chimeric baculoproteins eliminate disease-causing activities of PF and PV IgG fractions, respectively. Further, IgGs eluted from recombinant Dsg molecules elicit acantholysis and gross skin blisters in neonatal BALB/c mice (1923). Surprisingly, although both the recombinant protein representing the extracellular epitope of Dsg 3 and a chimeric baculoprotein combining sequences of the extracellular epitope of Dsg 3 and of the Fc portion of human IgG1 effectively absorb anti–Dsg 3 antibody from PV sera, only absorption on the chimeric baculoprotein can eliminate the antibodies capable of causing gross skin blisters in neonatal mice. The explanation for this phenomenon is that addition of the Fc IgG1 portion assists the Dsg 3 portion to fold properly and acquire an “active” conformation; however, confirmation that rDsg3-Ig-His absorbs only antibodies to Dsg 3 was not provided.

Using Dsg 3–deficient mice, we have recently demonstrated that the PV IgGs lacking anti–Dsg 1 antibody can (a) produce a PV-like, fishnet staining pattern of the epidermis when used in indirect immunofluorescence (IIF) reactions; and (b) induce clinical and histological signs of PV when injected intraperitoneally into Dsg3null neonates (1). Furthermore, we have shown rDsg3-Ig-His can absorb the non–Dsg 3 antibodies that are pathogenic in Dsg3null neonates (24). These results indicated that non–Dsg 3 PV antibodies mediate acantholysis but could not eliminate a possibility that the undetected anti–Dsg 1 antibody contributed to acantholytic activity of test PV IgGs in Dsg3null pups, because (a) 25–60% of patients with PV have both anti–Dsg 1 and anti–Dsg 3 antibodies, as demonstrated by immunoprecipitation (25, 26), immunoblotting (2729), and immunohistochemistry (30); (b) spread of lesions from the oral mucosa to the skin in one patient with PV was reported to be associated with the appearance of anti–Dsg 1 antibody (31); and, most importantly, (c) absorption of PV IgGs with rDsg1 was reported to eliminate the disease-causing activity, whereas the anti–Dsg 1 PV IgG was suggested to play a critical role in induction of PV-like deep suprabasilar acantholysis in Dsg3null neonates (32).

In this study, we attempt to resolve the controversy about the role of anti-Dsg antibodies in pemphigus. First, we demonstrate that antibodies targeting Dsg 1 and Dsg 3 are not essential for induction of PV-like lesions in neonatal mice and that PV antibodies to other keratinocyte self-antigens are sufficient for causing gross skin blisters. Second, we reveal the lack of monospecificity of the rDsg1-Ig-His and rDsg3-Ig-His chimeric baculoproteins for anti–Dsg 1 and anti–Dsg 3 antibodies, respectively. Third, we document that PV IgG fraction containing anti–Dsg 3 antibody without anti–Dsg 1 antibody or PV IgG fraction containing both anti–Dsg 1 and anti–Dsg 3 antibodies produce deep suprabasilar acantholysis in either wild-type or Dsg3null mice, whereas PF IgG fraction containing anti–Dsg 1 antibody without anti–Dsg 3 antibody produces subcorneal acantholysis localized to the granular layer. The cumulative results obtained in this study indicate that non-Dsg antibodies are sufficient to induce PV-like pathology in neonatal mice. Lesions in patients with PV may therefore result from cumulative and/or synergistic effects of a set of autoantibodies targeting different specific self-antigens on the keratinocyte cell surface.


Pemphigus and control sera, and IgG fractions.

The results reported here were obtained in experiments using sera and IgG fractions from patients with well-established PV and PF, and healthy volunteers. This study had been approved by the University of California Davis Human Subjects Review Committee. The diagnosis of PV or PF was made based on the results of both comprehensive clinical and histological examinations and immunological studies, including direct immunofluorescence (DIF), IIF on various epithelial substrates, immunoblotting, and immunoprecipitation, following standard protocols (33). The serum IgG fractions were isolated using 40% ammonium sulfate followed by dialysis against PBS (Life Technologies Inc., Gaithersburg, Maryland, USA), lyophilized and reconstituted in PBS as detailed elsewhere (1). The protein concentration was determined using the Micro BCA kit (Pierce Chemical Co., Rockford, Illinois, USA). The serum level of rheumatoid factor was measured by a standard nephelometric technique using a commercially available antigen (Kit P/N 465320; Beckman Instruments Inc., Brea, California, USA). According to the reference range used in the clinical laboratory of University of California Davis Medical Center, normal values do not exceed 20 IU/ml.

Enhanced sensitivity immunoprecipitation assay.

Cultures of epidermal keratinocytes used for metabolic radioactive labeling were established from normal human neonatal foreskins and grown to approximately 95% confluence in 150 cm2 flasks (Corning Costar, Cambridge, Massachusetts, USA) in serum-free keratinocyte growth medium (KGM; Life Technologies Inc.) containing 0.09 mM Ca2+ at 37°C in a humid 5% CO2 incubator, as described previously (34). Cultured keratinocyte monolayers were metabolically labeled for 16 hours at 37°C with 100 μCi/mL [35S]methionine (1,000 Ci/mmol; Amersham Life Science Inc., Arlington Heights, Illinois, USA) in 1.8 mM Ca2+ labeling medium, and the [35S]methionine-labeled proteins were separated by centrifugation and used as a source of naturally folded keratinocyte proteins in an immunoprecipitation assay (25). The immune complexes were precipitated with a protein A-Sepharose suspension (Sigma Chemical Co., St. Louis, Missouri, USA), washed, and resolved on SDS-PAGE gels. The gels were fixed, enhanced, and the radioactivity was analyzed using the storage phosphor autoradiography feature of the Storm system (Molecular Dynamics, Mountain View, California, USA), as described by us previously (35). The presence of Dsg 1 antibody in test sera was investigated using the 45-kDa tryptic fragment of Dsg 1 representing its immunoreactive epitope (36). Briefly, [35S]methionine-labeled keratinocytes were homogenized in 10 mM Tris-buffered saline containing 0.025% NaN3, and 20 mM Ca2+ (TBS-Ca) buffer containing 0.25% bovine trypsin (Sigma Chemical Co.) and then incubated for 1 hour at 37°C. The trypsinized homogenate was treated with 1 mM PMSF to stop the reaction, centrifuged at 40,000 g, and the supernatant was passed through a Concanavalin A Sepharose column (Con-A) (EY Laboratories Inc., San Mateo, California, USA). The Con-A–bound glycoproteins containing the 45-kDa immunoreactive epitope of Dsg 1 were eluted with 0.2 M α-methylmannoside (Sigma Chemical Co.), dialyzed against TBS-Ca, concentrated by lyophilization and used in enhanced sensitivity immunoprecipitation assay (ESIA) as a source of antigen.


The reactivity of test sera with the extracellular portions of the Dsg 1 or Dsg 3 peptide sequences that reportedly represent pathogenic epitopes of the PV or PF antigens (3739) was determined using Dsg 1– and Dsg 3–coated ELISA plates purchased from MBL (Nagoya, Japan), including the positive and the negative controls, and following the protocols provided by the manufacturer. All serum samples were tested in duplicate or triplicate on at least two different occasions, using different lots of ELISA plates, and the results were expressed as ELISA scores, or index values (IVs), calculated as follows: IV = (OD sample – OD negative control)/(OD positive control – OD negative control) × 100. As recommended by the manufacturer, a serum sample was considered to be positive for Dsg 1 or Dsg 3 antibody if the IV exceeded 20.

The samples of the PV, PF and normal human control sera used in this study were also independently tested in the laboratory of L.A. Diaz at Medical College of Wisconsin using the Dsg 1 ELISA developed in this laboratory.

In vitro model of pemphigus.

The standard protocols for treatment of normal human skin organ cultures with pemphigus serum (40, 41) were modified to eliminate known shortcomings. The samples of normal facial skin freshly removed from adult Caucasians undergoing surgical procedures were freed of fat and clotted blood, and 3-mm-diameter samples were obtained using a standard skin biopsy punch. These skin samples were rinsed in PBS, placed in plastic tubes containing ice-cold KGM without supplements, transported to the laboratory, and used in experiments immediately. The skin samples, containing epidermis and papillary and reticular dermis, were placed into the wells of the standard U-bottom 96-well cell-and-tissue culture plates (Falcon-Becton Dickinson Labware, Lincoln Park, New Jersey, USA), and 200 μL of test serum was added to each well. Each serum was tested in triplicate skin samples. The dishes were incubated at 37°C in a humid 5% CO2-containing atmosphere for 24, 36, 48, 72, and 96 hours. After each incubation period, the skin samples were harvested and examined by both light microscopy and DIF.

In vivo model of pemphigus.

The skin blisters were induced in neonatal mice by passive transfer of serum IgG fraction (42). This study had been approved by the University of California Davis Review Committee on the Use of Animals in Research. The IgGs were injected intraperitoneally through a 30-gauge needle into 10- to 12-hour-old pups at the doses specified in Results. The neonates in each progeny always received the same amount of test or control IgG. The latter was isolated from normal human serum purchased from Sigma Chemical Co. Both Dsg 3–containing BALB/c mice, and Dsg 3–deficient Dsg3null and C57BL/6 Dsg3bal/Dsg3bal mice were used (17). The integument of mice lacking Dsg 3 is normal at birth, making these neonates a suitable model for induction of pemphigus phenotype in passive transfer experiments (1, 32). In each litter, the lack of Dsg 3 in pups with induced blisters was confirmed by genotyping at the end of each passive transfer experiment. PCR was used to amplify the genomic sequences from the DNA isolated from pieces of mouse tails. The genotyping of Dsg3null mice was performed using PCR primers and reaction conditions described by us previously (1). The genotyping of Dsg3bal/Dsg3bal mice was performed by sequencing the PCR product that amplified a portion of the exon 14 of the Dsg3 gene containing the 2275insT functional null mutation. The sense 5′-gccatagcatgaactgttag-3′ and antisense 5′-gttggcttgtcttgtgagtt-3′ primers (Bio-Synthesis Inc., Lewisville, Texas, USA) were used in PCR and the amplification condition included preheating at 94°C for 4 minutes; hot start with Taq DNA polymerase (Promega Corp., Madison, Wisconsin, USA), then 35 cycles at 94°C for 1 minute, 60°C for 1 minute, and 72°C for 3 minutes. The knockout Dsg3null mice were homozygous for a targeted mutation of the Dsg3 gene, and “balding” Dsg3bal/Dsg3bal mice were homozygous for a spontaneous null mutation of the Dsg3 gene (17).

Immunoaffinity absorption experiments.

For preabsorption of antibodies to Dsg 1 and 3, we used the baculoproteins Dsg1-Ig-His, Dsg3-His, and Dsg3-Ig-His produced in High Five cells grown in Sf-900 II SFM medium (Life Technologies Inc.). The baculoviruses provided by M. Amagai (Keio University, Japan) were amplified in Sf9 insect cell (Life Technologies Inc.), and the preabsorption experiments were performed exactly as described by Amagai et al. (23). Briefly, supernatant containing each recombinant protein was incubated with TALON metal affinity resin overnight at 4°C with gently rocking. After washing ten times with PBS containing 1 mM CaCl2, the TALON resins carrying immobilized baculoproteins were incubated with PV serum overnight. The resins with bound antibodies were washed 15 times with PBS, and the antibodies were eluted with an IgG gentle elution buffer (Pierce Chemical Co.). The eluants were cleared on D-Salt Excellulose Plastic Desalting Column (Pierce Chemical Co.) and diluted in TBS containing 2% nonfat milk and 10 mM CaCl2.

For preabsorption of antibodies to the Fc portion of human IgG, we used the Ig-immunosorbent column containing Sepharose conjugated with the Fc fragment of human IgG (Bethyl Laboratories, Inc., Montgomery, Texas, USA), and the incubation and elution procedures already described here. The efficiency of adsorption of anti-Fc IgG antibodies on this column was tested by the ability of the preabsorbed FITC-conjugated goat anti-human Fc IgG antibody (Sigma Chemical Co.) to visualize PV IgG bound to monkey esophagus in a standard IIF assay. The amount of adsorbed anti-Fc IgG antibodies was monitored by measuring the protein concentration in test IgG fraction before and after its absorption and comparing the differences with the protein concentration of the eluant.

Characterization by immunoblotting of antigenic reactivities of adsorbed PV IgGs.

The PV IgGs eluted from Dsg 1 and Dsg 3 constructs and from the Ig-immunosorbent column were characterized by immunoblotting using as substrate protein the extracts of normal human keratinocytes and keratinocytes from Dsg 3–positive BALB/c or Dsg 3–negative Dsg3null mice that were resolved by SDS-PAGE and transferred to nitrocellulose membrane (Millipore Corp., Bedford, Massachusetts, USA), as detailed previously (24). The immunoblotting membranes were blocked with 5% nonfat milk in 20 mM Ca2+ -containing TBS (pH 7.4) for 1 hour at 37°C. The blots were cut into 4-mm–wide vertical strips, and each strip was exposed overnight at 4°C to an affinity-purified PV IgG diluted in TBS containing 1% normal goat serum, 3% nonfat milk, and 0.05% Tween 20 (Sigma Chemical Co.). Binding of primary antibody was visualized using horseradish peroxidase (HRP) conjugated goat anti-human IgG (Pierce Chemical Co.) with an HRP color developer (Bio-Rad Laboratories Inc., Hercules, California, USA). The specificity of binding was determined in negative control experiments, in which the primary antibody was omitted.

In a separate set of immunoblotting experiments, we examined antigenic reactivities of PV IgGs eluted from distinct keratinocyte protein bands, in accordance with the procedure for immunoaffinity antibody purification (43). Briefly, approximately 3-mm–wide horizontal strips carrying a keratinocyte protein with a specific Mr ± 3 kDa were cut out from the immunoblotting membrane and incubated overnight with PV IgG serum fraction diluted 1:5 in TBS containing 20 mM CaCl2, 0.05% Tween 20 (Sigma Chemical Co.) and 1% nonfat milk to allow antibody binding. The strips were then washed thoroughly, and the IgGs were eluted by a 3-minute incubation at 37°C in a solution containing 500 μL of 20 mM sodium citrate, 1% milk, and 0.05% Tween 20 (pH 3.2), and immediately neutralized by adjusting the pH to 7.4 with the 2 M Tris base.


Characterization of Dsg 1 and Dsg 3 antibody profiles of PV and PF sera.

The profile of anti-keratinocyte antibodies present in the sera of patients with PV was characterized by ESIA, using radiolabeled, naturally folded Dsg 1 and Dsg 3, and ELISA, using recombinant proteins representing the extracellular domains of Dsg 1 and Dsg 3 (Figure (Figure1).1). By both ESIA and ELISA, all PV sera, but not normal human or PF sera, contained autoantibody to the 130-kDa Dsg 3. In ESIA, the PV1 and PV2 sera did not precipitate the 160-kDa Dsg 1 nor its 45-kDa tryptic fragment (Figure (Figure1),1), which constitutes the major antigenic region for anti–Dsg 1 PF autoantibody and has been shown to be a very sensitive and specific probe for the anti–Dsg 1 antibody developed by patients with PV (31). Both PV1 and PV2 sera were also found negative for Dsg 1 antibody in ELISA assays (Figure (Figure1).1). The commercial Dsg 1 ELISA kit used in our laboratory contained recombinant Dsg 1 developed by Amagai et al. (37). These negative results were confirmed in ELISA experiments performed in Diaz’s laboratory (data not shown), using recombinant Dsg 1 developed by Ding et al. (44).

Figure 1
Characterization of PV and control sera. To identify the profiles of anti-keratinocyte antibodies, whole-cell (top) or 0.25% trypsin-digested (bottom) protein extracts of [35S]methionine-labeled human keratinocytes were immunoprecipitated ...

To eliminate the possibility that the autoantibodies to the conformational epitope of Dsg 1 remained undetectable in ESIA and ELISA due to limitations of these assays, we included PV3 serum and the PF serum as positive controls. These sera reacted with the 160-kDa Dsg 1 that was present in the keratinocyte protein solution used in ESIA (Figure (Figure1).1). These two positive control sera also immunoprecipitated the 45-kDa fragment of Dsg 1 in ESIA and showed high titer of anti–Dsg 1 antibodies in ELISA (Figure (Figure11).

As negative controls, we used the sera from two healthy subjects without history of any blistering skin condition. These sera immunoprecipitated none of 130- or 160- or 45-kDa keratinocyte polypeptides in ESIA and were negative for Dsg 1 and Dsg 3 antibodies in ELISA (Figure (Figure11).

Thus, the four different approaches to detect Dsg 1 antibody in PV1 and PV2 sera produced negative results.

Is anti–Dsg 3 antibody the sole mediator of PV lesions?

Mice lacking Dsg 3 do not spontaneously develop gross skin blisters (1, 16, 17). If Dsg 3 is indeed essential for normal keratinocyte cell-to-cell adhesion in normal epidermis, the lack of skin lesions in Dsg3null and Dsg3bal/Dsg3bal mice may be explained by a compensation mechanism in which upregulation of other adhesion molecules occurs. Therefore, these animals provide a unique Dsg 3–free system for probing PV sera for the presence of non–Dsg 3 autoantibodies targeting the molecules that mediate and regulate keratinocyte cell-to-cell adhesion in the epidermis (1, 32). To determine whether non–Dsg 1/non–Dsg 3 PV antibodies are sufficient at causing skin blisters, we selected the two PV sera (PV1 and PV2) that did not contain Dsg 1 antibody, isolated IgG fractions and injected them intraperitoneally through a 30-gauge needle at a dose of 20 mg/1 g body weight into 10- to 12-hour-old offsprings bred from homozygous female and male Dsg3null mice, as well as litters resulting from breeding pairs of homozygous Dsg3bal/Dsg3bal mice. Control littermates received the same doses of IgG isolated from pooled normal human serum (control). All neonates injected with PV IgGs (Figure (Figure2;2; n = 16), but not with normal human IgG (n = 12; data not shown), developed extensive, flaccid skin blisters approximately 18–24 hours after a single injection. The blisters resulted from suprabasilar acantholysis associated with binding of non–Dsg 1/non–Dsg 3 antibodies to the cell surface of murine epidermal keratinocytes (Figure (Figure2).2). Identical clinical and microscopic features were produced in normal BALB/c mice by PV1 (n = 4) or PV2 (n = 6) IgGs (data not shown).

Figure 2
Induction of pemphigus in neonatal mice lacking Dsg 3 by passive transfer of IgGs from sera of PV patients that lack Dsg 1 antibody. Neonatal knockout Dsg3null mice homozygous for a targeted mutation of the Dsg3 gene (ad) and “balding” ...

To eliminate the possibility that pups with blisters developed a revertant mutation that restored expression of the Dsg3 gene, the expected genotypes of all pups was confirmed at the end of each experiment (data not shown).

Thus, PV-like skin lesions in neonatal mice can be produced by PV autoantibodies to keratinocyte proteins other than Dsg 1 and Dsg 3.

Does Dsg 1 antibody contribute to acantholytic activity of PV serum?

The results discussed here indicated that anti-Dsg 3 antibody may not be critical for skin blister formation in patients with PV, in agreement with the conclusion of Mahoney et al. (32) that anti–Dsg 3 alone is not sufficient at causing skin blistering. However, the possibility that in our passive transfer experiments the skin lesions were caused by a “hidden” anti-Dsg 1 antibody could not be excluded because, theoretically, this antibody might not recognize the conformational epitopes of any Dsg 1 molecules present in either antigenic substrate used by four different antibody detection assays (Figure (Figure1).1). Although patients with PV never develop the superficial epidermal acantholysis seen with anti–Dsg 1 (44), this antibody still may be pathogenic. If so, the lack of PF-like pathology in patients with PV might be explained by prevention of anti–Dsg 1 antibody entry of the granular cell layer by the deep suprabasilar split in the epidermis of these patients. We tested this hypothetical mechanism using an in vitro model of PV in which all epidermal layers are equally accessible to antibodies. The normal human skin specimens were bathed in the medium containing pemphigus antibodies for different time periods, and penetration of the antibodies throughout all epidermal layers with their subsequent deposition on the cell membrane of keratinocytes was confirmed by DIF. We tested (a) PV serum containing anti–Dsg 3 antibody without anti–Dsg 1 antibody (PV2 serum); (b) PV serum with both anti–Dsg 1 and anti–Dsg 3 antibodies (PV3 serum); (c) PF serum featuring anti–Dsg 1 antibody without anti–Dsg 3 antibody; and (d) a healthy volunteer serum (N2, i.e., normal serum 2 in Figure Figure1).1). The first signs of acantholysis in skin organ cultures treated with pemphigus sera could be observed as early as 24 hours of incubation (data not shown). Extensive acantholysis with wide intraepidermal clefting was observed by the end of the second day of incubation. After the 4th day, nonspecific changes, such as keratinocyte apoptosis and vacuolar and ballooning alterations, could be observed in the epidermis of all skin organ cultures. Therefore, all experiments were terminated at 72 hours of incubation, and the changes produced by test sera by that time point were compared.

As seen in Figure Figure3,3, the PV2 serum containing the 130-kDa Dsg 3 antibody caused deep suprabasilar acantholysis. The basal cells remained attached to the basement membrane, rendering the tombstone appearance, which is the histopathological hallmark of PV (45). The PF serum with the 160-kDa Dsg 1 antibody produced acantholysis in the superficial layer of the epidermis (Figure (Figure3).3). The split occurred within the granular cell layer. In marked contrast, the PV3 serum that, in addition to anti–Dsg 3 antibody, also contained anti–Dsg 1 antibody caused only suprabasilar acantholysis, but no superficial split that would be expected if anti–Dsg 1 PV antibodies were pathogenic (Figure (Figure3).3). When these skin organ cultures were examined by DIF, the IgGs present in all three test pemphigus sera stained the entire epidermis, including the granular cell layer, in a similar intercellular, pemphigus-like pattern, which is consistent with the general observations that the DIF patterns of PV and PF sera are indistinguishable in most cases (46).

Figure 3
Characterization of acantholytic activities of pemphigus sera with different combinations of Dsg 1 and Dsg 3 antibodies in skin organ culture. The anti-keratinocyte antibody profiles of two Dsg 3 antibody–positive PV sera, one with (PV3) and one ...

To distinguish pemphigus antibody–induced effects from nonspecific or degenerative changes in the cultured epidermis, parallel skin samples from the same skin donor were incubated with normal human sera. The bottom row of Figure Figure33 shows that no alterations of the integrity of the epidermis or any deposits of IgG could be detected in the cultures incubated with the N2 serum for 4 days.

Thus, anti–Dsg 1 antibody present in PV serum does not exhibit acantholytic activity at its normal serum concentration, in agreement with the findings of Ding et al. (44).

Can anti–Dsg 1 antibody cause PV-like skin lesions in Dsg3null mice?

A role for anti–Dsg 1 antibody in PV was proposed in the “desmoglein compensation” hypothesis (47), which is based on a report that both PV and PF IgGs produce identical suprabasilar split in Dsg3null mice (32). The hypothesis attempts to reconcile the discrepancy between the known correlation of anti–Dsg 1 antibody with subcorneal epidermal split of PF and suprabasilar location of acantholysis in PV. However, insufficient thickness of murine epidermis may have hampered localization of the split. Therefore, in this study we compared the epidermal morphology at different anatomical regions of wild-type and Dsg3null mice.

The IgG fractions of PF sera and PV3 sera, both of which contained anti–Dsg 1 antibody (Figure (Figure1),1), were injected intraperitoneally at a dose of 10 mg/g body weight into 10- to 12-hour-old Dsg3null mice (16 pups received PF IgG; seven pups received PV3 IgG) or BALB/c mice (nine pups received PF IgG; five pups received PV3 IgG), and skin samples were obtained 24 hour thereafter. Both strains of mice injected with PF IgG developed superficial skin peeling, or wrinkling, with a positive Nikolsky sign (Figure (Figure4a).4a). Light microscopic examination revealed superficial, or subcorneal, epidermal acantholysis, as in patients with PF (Figure (Figure4b).4b). However, in locations where the basal cell layer was the only nucleated cell layer of the epidermis (Figure (Figure4,4, b and c; arrows), the subcorneal split appeared as a suprabasilar split. The morphological pattern shown in Figure Figure4b4b was seen in the specimens obtained from the head/neck and axillary areas, where the epidermis is relatively thick, whereas the pattern seen in Figure Figure4c4c could be observed in skin of the trunk and extremities, where epidermis is thinner. In marked contrast, all pups injected with PV3 IgGs (Figure (Figure4d)4d) showed clinical and morphological acantholysis that was indistinguishable from that seen in mice injected with the PV IgGs that did not contain anti–Dsg 1 antibody. The deep intraepidermal localization of the acantholytic cleft, which was obvious in the skin areas with thick epidermis (Figure (Figure4d),4d), confirmed that the split induced by PV IgGs in the abdominal skin of Dsg 3–deficient mice, where the epidermis is thin (Figure (Figure2,2, c and g), was also suprabasilar rather then subcorneal. The subcorneal split was never found in skin specimens from mice injected with the PV IgGs that were either positive or negative for anti–Dsg 1 antibody.

Figure 4
Passive transfer of PV and PF IgGs to neonatal Dsg3null mouse produce two distinct phenotypes in the epidermis. The PF IgG that immunorecognized Dsg 1 and did not cross-react with Dsg 3 and the PV3 IgG that contained antibodies to both Dsg 1 and Dsg 3 ...

Thus, upon passive transfer to neonatal Dsg3null mice, PV or PF IgGs produce two distinct, PV-like or PF-like phenotypes, respectively, eliminating the possibility that gross skin blisters and deep suprabasilar acantholysis in Dsg 3–lacking mice injected with PV IgGs (Figure (Figure2)2) were caused by any unidentified anti–Dsg 1 antibody. The PV-like skin lesions were therefore induced by non–Dsg 1/non–Dsg 3 antibodies.

Do Dsg 1 and Dsg 3 chimeric baculoproteins absorb similar disease-causing non-Dsg PV antibodies?

These results provided evidence that non–Dsg 1/non–Dsg 3 antibodies can cause skin blisters in patients with PV. How then could Dsg 1 and Dsg 3 constructs absorb out all disease-causing PV antibodies in previous studies (21, 23, 32, 48)? Because the antigenic profile of the eluted PV IgGs was not characterized in those studies, the issue of monospecificity of the recombinant Dsg proteins used in absorption experiments required examination. We therefore produced the recombinant baculoproteins using the baculoviruses provided by M. Amagai, repeated the absorption experiments exactly as described in the original studies (21, 23), and characterized the immunoreactivities of the eluted, disease-causing PV IgG by immunoblotting using different keratinocyte substrates. Preliminary results indicated that the antigenic profiles of PV IgG eluted from rDsg3-His and rDsg3-Ig-His are different, suggesting that addition of the Fc IgG portion to the extracellular portion of Dsg 3 created a new epitope recognized by pathogenic non–Dsg 3 PV IgG (24). Alternatively or additionally, rDsg3-Ig-His might absorb anti-Fc IgG antibody (also known as rheumatoid factor). To test this hypothesis, we in this study compared the antigenic profiles of PV IgGs eluted from the rDsg3-His versus rDsg3-Ig-His versus rDsg1-Ig-His versus Fc IgG columns. The authenticity of the Dsg3-His, Dsg3-Ig-His and Dsg1-Ig-His baculoviruses was verified by PCR (Figure (Figure5a),5a), and the reactivities of produced baculoproteins with PV antibodies were confirmed by immunoblotting (Figure (Figure5b).5b). The efficiency of the Fc IgG column in absorbing ant-Fc IgG antibodies was demonstrated by the ability of the FITC-conjugated goat anti-human Fc IgG antibody that was first preabsorbed on and then eluted from the column to visualize PV IgG bound to the monkey esophagus substrate in a standard IIF assay (data not shown).

Figure 5
Characterization of rDsg1-Ig-His, rDsg3-His, and rDsg3-Ig-His baculoviruses and baculoproteins. (a) PCR amplifications of DNA isolated from High Five insect cells infected with the rDsg3-His (lanes 2 and 3), rDsg3-Ig-His (lanes 5 and 6), or rDsg1-Ig-His ...

The antigenic profile of PV IgGs adsorbed on each recombinant protein was characterized by immunoblotting (Figure (Figure6).6). The PV3 IgG eluted from rDsg3-His recognized mainly the 130-kDa human keratinocyte protein but also stained weakly a few bands with lower relative molecular mass. The PV3 IgG eluted from rDsg3-Ig-His reacted with a mixture of protein bands, including a 130-kDa polypeptide present in Dsg3null keratinocytes (Figure (Figure6).6). Most of protein bands visualized by PV3 IgG eluted from rDsg1-Ig-His showed molecular weights that were very similar to those visualized by PV3 IgG eluted from rDsg3-Ig-His (Figure (Figure6).6). The PV3 IgG eluted from the Fc IgG column (~12 mg total) did not recognize murine epidermal proteins in either Western blotting (Figure (Figure6)6) or IIF (data not shown) assays. However, given that PV3 serum contained a rheumatoid factor (62 IU/ml), to rule out even a remote possibility that this antibody could induce skin changes in vivo, we tested PV3 IgG eluted from the Fc IgG column in passive transfer experiments with Dsg 3–deficient neonatal mice. We could not find any gross or microscopic skin changes, elicit Nikolsky sign, or detect any specific antibody binding to the epidermis in any of the four Dsg3bal/Dsg3bal mice that were injected subcutaneously with 1.5 mg/g body weight of affinity-purified anti-Fc IgG antibody and observed for at least 24 hours after injection after which the animals were sacrificed. These results showed that the anti-Fc IgG antibody present in the PV3 IgG fraction does not cross react with keratinocyte proteins by immunoblotting and IIF, does not bind to the epidermis of Dsg 3 deficient mice in vivo and does not cause any skin changes in passive transfer experiments. This antibody, therefore, could not contribute to the staining of murine epidermal proteins and intraepidermal blisters produced by PV3 IgG eluted from the rDsg3-Ig-His construct.

Figure 6
The profiles of the PV IgGs absorbed by recombinant Dsg 1 and Dsg 3 baculoproteins. Western blots of protein extracts of normal human keratinocytes resolved by 7.5% SDS-PAGE and stained with PV3 IgG affinity-purified on rDsg3-His (lane 1), and ...

Most likely, addition of the Fc IgG1 sequence to the Dsg 1 and Dsg 3 extracellular epitopes rendered novel secondary or tertiary structures to these adhesion molecules. If the newly formed antigenic epitope represented conformational epitope of Dsg 3, then multiple bands visualized by PV3 IgGs eluted from rDsg1-Ig-His or rDsg3-Ig-His would result from random cross-reactivities of anti-Dsg 3 antibodies with other keratinocyte proteins. If these cross reacting anti-Dsg 3 autoantibodies were polyclonal, then anti-Dsg 3 IgG eluted from any single band should have been able to produce the same or very similar multiple-band staining pattern as the whole PV3 IgG fraction did. If the autoantibodies were monoclonal, then at least two bands, the 130-kDa band and the one from which that specific IgG was eluted, should have been visualized upon re-staining.

To examine these intriguing possibilities, we characterized the antigenic profile of PV3 IgG eluted from a horizontal 190-kDa band strip cut from a wide immunoblotting membrane. We selected this band based on the following two main reasons: (a) it had the highest relative molecular mass compared with other bands visualized by PV3 IgGs eluted from rDsg3-Ig-His, which excluded a possibility that it represented a degradation product of any desmosomal cadherin; and (b) it was located at the edge of the antigenic “ladder” visualized on the immunoblotting membrane, which diminished to the minimum a chance that the horizontal strip cut at this area of the membrane could carry any other pemphigus antigens. The experiments showed that only 190-kDa band, but not 130- or 160-kDa band or any other band with a low relative molecular mass, could be stained with the antibody eluted from 190-kDa area of the immunoblotting membrane (Figure (Figure6).6). These results indicate that the disease-causing PV IgGs absorbed with rDsg3-Ig-His represent a mixture of autoantibodies to an array of new keratinocyte self-antigens, including yet unidentified non–Dsg 3 polypeptides with apparent Mr of 190 and 130 kDa. These results also indicate that the protein bands with lower relative molecular mass recognized by PV IgG eluted from the chimeric baculoproteins do not represent degradation products of the 190-kDa pemphigus antigen.

Thus, Dsg 3 chimeric baculoprotein absorbs out all disease-causing PV antibodies nonspecifically, perhaps due to creation of new secondary or tertiary epitopes as a result of unique folding of the chimeric baculoprotein composed of two unrelated polypeptide sequences.


In this study, we demonstrate for the first time that, in addition to Dsg 1 and Dsg 3, other keratinocyte proteins can be targeted by disease-causing PV antibodies and that neither anti–Dsg 1 nor anti–Dsg 3 antibody is critical for induction of PV-like skin blisters. These results were obtained in in vitro and in vivo models of pemphigus, using a novel, high sensitivity-and-specificity metabolic uptake assay, ESIA, in combination with the ELISA that uses supposedly pathogenic recombinant extracellular epitopes of Dsg 1 and Dsg 3. The discrepancy of these results with the postulated exclusive roles of anti–Dsg 1 and anti–Dsg 3 antibodies in mediating clinical and microscopic signs of pemphigus can be explained by our findings that both rDsg1-Ig-His and rDsg3-Ig-His chimeric baculoproteins, in addition to absorbing the purportedly unique autoantibodies against the adhesion molecules Dsg 1 and Dsg 3, also absorb a heterogeneous group of autoantibodies targeting other keratinocytes proteins.

Blisters in pemphigus occur by intraepidermal clefting that results from breakdown of cell-to-cell adhesion. Intercellular spaces enlarge; desmosomes decrease in number and eventually disappear; and the cells round up and detach from one another without cell death (acantholysis) (45, 4951). Blisters in pemphigus are associated with the binding of IgG autoantibodies to the keratinocyte cell surface (52). The pathophysiological importance of anti-Dsg autoimmunity in pemphigus has been suggested (810) by the results of experiments showing the ability of recombinant Dsg 1 and Dsg 3 constructs to absorb disease-causing antibodies from PF and PV sera, respectively (2123). Validity of this theory was diminished when marked epidermal acantholysis and extensive skin blistering was induced in otherwise normal Dsg3null neonatal mice by passive transfer of PV IgGs (1). As was determined by immunoblotting and standard immunoprecipitation techniques, the PV IgG fractions injected into Dsg 3–deficient mice did not contain anti–Dsg 1 antibody (1). However, it has been recently reported that absorption of PV sera with recombinant Dsg 1 could eliminate all disease-causing activity in passive transfer experiments with Dsg3null mice, suggesting that anti–Dsg 1 antibody is responsible for the PV-like phenotype in these pups (32). Therefore, in our previous study (1) the disease-causing anti–Dsg 1 antibodies might have been undetectable due to destruction of conformational epitope of Dsg 1 in the course of immunoblotting and/or relatively low sensitivity of the standard immunoprecipitation assay used.

In this study, the anti-keratinocyte antibodies developed by patients with pemphigus were characterized using naturally folded keratinocyte proteins as antigens. We used the enhanced sensitivity metabolic labeling assay, ESIA, in which the sensitivity and resolution is enhanced by the ability of the Storm system’s phosphor-imager feature to capture the image from both strong and weak signals in a single exposure (53, 54). To increase the sensitivity of our detection technique even further, we probed the sera with a 45-kDa immunoreactive fragment of Dsg 1 purified by Con A affinity chromatography (36). The 45-kDa polypeptide is a fragment of Dsg 1, as can be judged from the sequencing data reported by Abreu-Velez et al. (55), and is believed to be a very sensitive probe for anti–Dsg 1 antibody produced by patients with PV (31). Finally, to validate the sensitivity of our approach, we performed series of ELISA experiments using as antigens the extracellular epitopes of Dsg 1 and Dsg 3 that have been reported to be highly sensitive and specific targets for pathogenic anti-Dsg antibodies produced by patients with different forms of autoimmune pemphigus (23, 37, 39, 44, 56). This combination of highly sensitive and specific immunoassays was required to identify the PV sera that were free of anti-Dsg 1 antibody in order to test their acantholytic activities in vivo and in vitro.

The IgG fractions of Dsg 1 antibody–negative PV sera caused gross skin blisters with suprabasilar acantholysis and produced a fishnet-like, intercellular staining pattern of perilesional epidermis in two different strains of mice lacking Dsg 3. By ESIA, in addition to the 130-kDa Dsg 3 target that was absent in these mice, the non–Dsg 1 pathogenic PV IgGs uniquely recognized keratinocyte proteins of approximately 38, 43, 115, and 190 kDa. The possibility that the anti–Dsg 3 antibody cross-reacted with Dsg 1 on the cell surfaces of murine keratinocytes, leading to acantholysis via this pathway, is unlikely because Dsg 3 antibody produced by patients with PV does not cross-react with Dsg 1 (44, 56). This was confirmed in this study by lack of protein bands with apparent Mr of 160 kDa in Western blots stained with the Dsg 1 antibody–positive PV3 IgG eluted from rDsg3-His or rDsg3-Ig-His. Furthermore, a semiquantitative IIF assay shows that the epidermis of Dsg3null mice immunoreacts with only 58% of the relative amounts of PV IgGs bound in the epidermis of the Dsg3+/+ BALB/c mice, defined as 100%, indicating that anti–Dsg 3 antibody present in PV IgG fractions does not bind to the Dsg 3–negative keratinocytes (1). Indeed, commercially available antibody to Dsg 3 also does not stain the epidermis of Dsg3null and Dsg3bal/Dsg3bal mice (1). Furthermore, the results of our organ culture experiments demonstrate that anti–Dsg 1 antibody present in PV sera is unable to induce superficial acantholysis characteristic of PF.

Thus, PV-like skin lesions in Dsg 3–deficient mice injected with PV IgG mice seemed to be induced through a pathophysiological mechanism exclusive of any Dsg 1 and Dsg 3 antibody–mediated pathways. However, the ultimate conclusion could not be made until after resolution of the controversy about microscopic localization of skin blisters in Dsg3null neonatal mice injected with anti–Dsg 1 antibody (32, 48).

To address a hypothetical possibility that in our passive transfer experiments (Figure (Figure2)2) the skin blisters were caused by some hidden anti–Dsg 1 antibody, we investigated thoroughly the pathology of the skin of Dsg3null neonatal mice injected with the Dsg 1 antibody-containing PF IgG. We found the superficial intraepidermal split. However, the location of the split could be also called suprabasilar in anatomical regions where the basal cell layer was the only nucleated cell layer of the epidermis. Identical gross and microscopic changes were observed in wild-type Dsg 3–positive mice injected with PF IgGs. Therefore, as either Dsg3null or Dsg3bal/Dsg3bal or wild-type mice injected with PV IgG never develop any evidence of PF-like subcorneal split, but always demonstrate deep, suprabasal acantholysis, it is extremely unlikely that the PV-like phenotype in Dsg 3–negative neonates injected with PV IgG was caused by some hidden anti–Dsg 1 antibody. The keratinocytes in Dsg 3-negative mice, however, may be more sensitive to non-Dsg antibodies than in wild-type mice.

Having established that non–Dsg 1/non–Dsg 3 PV IgGs are capable of inducing PV-like skin blisters, we inquired how could the recombinant Dsg 1 and Dsg 3 constructs that also carry Fc IgG1 portion absorb out all disease-causing antibodies from PV sera (2123, 32)? Furthermore, in our own experiments, absorption of PV sera with rDsg3-Ig-His eliminated the ability of IgGs purified from these sera to cause acantholysis in Dsg 3-negative Dsg3null mice, whereas the PV IgG eluted from rDsg3-Ig-His induced skin blisters in these mice (24). Therefore, because the Dsg 3 antigen was not present in the epidermis of Dsg3null mice, the interpretations that rDsg3-Ig-His absorbs disease-causing PV IgGs due to a permissive conformation mimicking the authentic epitope, in contrast to rDsg3-His, which lacks this ability, and that its conformation is important in the pathogenesis of PV become untenable. To clarify the relevant mechanisms, we compared the antigenic profiles of PV antibodies absorbed by rDsg1-Ig-His and rDsg3-Ig-His. Both chimeric baculoproteins absorbed a series of autoantibodies, recognizing, in addition to the 160-kDa Dsg 1 and 130-kDa Dsg 3, respectively, keratinocyte proteins with apparent Mr of 38, 43, 115, and 190 kDa. These results strongly suggested that both chimeric baculoproteins absorb identical non-Dsg antibodies, and that addition of Fc portion of IgG1 to the extracellular epitopes of Dsg 1 and Dsg 3 accounts for similar antibody reactivities of both chimeras. Thus, the chimeric baculoproteins used in the past to remove disease-causing activity of PV and PF sera, which is the only evidence directly supporting the notion that anti–Dsg 1 and anti–Dsg 3 antibodies are pathogenic, actually absorbed out autoantibodies directed to multiple keratinocyte cell membrane proteins. Hence, although the conformational epitopes of these baculoproteins are indeed recognizable by disease-causing PV and PF antibodies, the autoantibodies are heterogeneous. These chimeras, therefore, may become a useful tool for elimination and further characterization of antibodies causing PV and PF.

Further investigation of PV and PF disease-causing antibodies may take advantage of recent discoveries of two new human keratinocyte molecules targeted by disease-causing PV IgGs, namely: (a) the α9 acetylcholine receptor with dual muscarinic-and-nicotinic pharmacology (24), and (b) pemphaxin, a novel annexin (also known as annexin 31 or ANXA9) that can act as an acetylcholine receptor (35). The pathophysiological importance of these new molecules in pemphigus is illustrated by the ability of rabbit monoepitopic anti-α9 antibody to cause pemphigus-like acantholysis in keratinocyte monolayers, and by elimination of the disease-causing activity of PV IgGs by preabsorption with recombinant pemphaxin. These observations are in keeping with earlier findings showing that 85% of patients with PV and of those with PF develop autoantibodies to keratinocyte acetylcholine receptors (1), and a large body of evidence demonstrating that pemphigus antibody binding to the keratinocyte cell membrane evokes a cascade of intracellular biochemical reactions (reviewed in refs. 1, 57), including those that directly alter expression and function of Dsg 3 (58, 59) and other adhesion molecules, such as vinculin and connexin 43 (60).

Acetylcholine receptors and annexins are functionally coupled to regulation of intracellular Ca2+ and control cell adhesion and motility (reviewed in refs. 61, 62). Recent studies of molecular mechanisms of epithelial adhesion have revealed that Ca2+-mediated actin-polymerization is the major driving force for keratinocyte cell-to-cell attachment and that desmosome assembly is a passive process that occurs once the stable cell-cell contact has been made (63). It is therefore worth noting that acantholysis and a loss of skin adhesion in Hailey-Hailey disease and in Darier disease result from defects in genes encoding an ATP-powered calcium pump that sequesters calcium in the Golgi apparatus (64) and a sarco/endoplasmic reticulum-Golgi calcium pump (65), respectively. Altogether, these findings elucidate, on the one hand, the morphological similarities between keratinocyte acantholysis induced by either cholinolytic drugs or pemphigus antibody, and, on the other hand, the ability of the cholinomimetic drugs to abolish PV IgG-induced acantholysis (reviewed in ref. 66).

In summary, the results of this comprehensive study reveal, for the first time to our knowledge, the following facts which will be critical in formulating further conclusions about the pathophysiology of PV: (a) PV-like skin lesions can be induced without participation of either anti-Dsg 1 or anti-Dsg 3 antibodies. (b) PV and PF IgGs produce different disease phenotypes in Dsg3null mice. (c) Absorption of similar non-Dsg antibodies with rDsg1-Ig-His and rDsg3-Ig-His reconciles the controversy about the role of anti-Dsg 1 and anti-Dsg 3 antibodies in pemphigus.

We conclude that acantholysis in PV is mediated by an active process triggered by a yet incompletely understood pathogenic mechanism, including autoantibodies to different types of keratinocyte cell membrane proteins. Our “multiple hit” hypothesis assimilates diverse postulates on the roles of different autoantibodies in pemphigus (66). We propose that antibody binding to multiple cell-surface target antigens induce acantholysis. The severity of disease and the specific clinical presentation in each particular patient depend on the contributions and relative concentrations of multiple anti-keratinocyte autoantibodies. Future studies, therefore, should be directed toward identification of the keratinocyte membrane proteins targeted by disease-causing antibodies in each patient with PV or PF, and elucidation of the immunopharmacological actions of novel disease-causing pemphigus IgGs.


We thank Peter M. Yau from the Department of Biochemistry, University of California Davis Medical School, for help with analysis of the radioactivity of immunoprecipitation gels on the Storm system. The colony of mice with targeted disruption of the Dsg3 gene was established from animals generously donated to The Induced Mutant Resource of The Jackson Laboratory by John R. Stanley (University of Pennsylvania). We thank Peter Koch (Baylor College of Medicine) for providing the primer sequences used for typing Dsg3null mice, and Masayuki Amagai (Keio University, Tokyo, Japan) for providing the Dsg1-Ig-His, Dsg3-His and Dsg3-Ig-His baculoviruses used to produce the respective baculoproteins for immunoadsorption experiments. This work was supported through the International Pemphigus Research Fund (S.A. Grando) and a grant (CA20408) from the National Institutes of Health (L.D. Shultz).


1. Nguyen VT, et al. The pathophysiological significance of non-desmoglein targets of pemphigus autoimmunity. Pemphigus vulgaris and foliaceus patients develop antibodies against keratinocyte cholinergic receptors. Arch Dermatol. 1998;134:971–980. [PubMed]
2. Stanley JR, Yaar M, Hawley-Nelson P, Katz SI. Pemphigus antibodies identify a cell surface glycoprotein synthesized by human and mouse keratinocytes. J Clin Invest. 1982;70:281–288. [PMC free article] [PubMed]
3. Stanley JR, Koulu L, Thivolet C. Distinction between epidermal antigens binding pemphigus vulgaris and pemphigus foliaceus autoantibodies. J Clin Invest. 1984;74:313–320. [PMC free article] [PubMed]
4. Stanley JR. Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases. J Clin Invest. 1989;83:1443–1448. [PMC free article] [PubMed]
5. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell. 1991;67:869–877. [PubMed]
6. Stanley JR, Koulu L, Klaus-Kovtun V, Steinberg MS. A monoclonal antibody to the desmosomal glycoprotein desmoglein I binds the same polypeptide as human autoantibodies in pemphigus foliaceus. J Immunol. 1986;136:1227–1230. [PubMed]
7. Korman NJ, Eyre RW, Klaus-Kovtun V, Stanley JR. Demonstration of an adhering-junction molecule (plakoglobin) in the autoantigens of pemphigus foliaceus and pemphigus vulgaris. N Engl J Med. 1989;321:631–635. [PubMed]
8. Hashimoto T. Cadherins and blistering skin diseases. Curr Opin Dermatol. 1993;2:244–249.
9. Amagai M. Adhesion molecules. I. Keratinocyte-keratinocyte interactions; cadherins and pemphigus. J Invest Dermatol. 1995;104:146–152. [PubMed]
10. Stanley JR. Defective cell-cell adhesion in the epidermis. Ciba Found Symp. 1995;189:107–120. [PubMed]
11. Stanley JR. Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion. Adv Immunol. 1993;53:291–325. [PubMed]
12. Hashimoto T, Amagai M, Garrod DR, Nishikawa T. Immunofluorescence and immunoblot studies on the reactivity of pemphigus vulgaris and pemphigus foliaceus sera with desmoglein 3 and desmoglein 1. Epithelial Cell Biol. 1995;4:63–69. [PubMed]
13. Amagai M, Koch PJ, Nishikawa T, Stanley JR. Pemphigus vulgaris antigen (desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients. J Invest Dermatol. 1996;106:351–355. [PubMed]
14. Rickman L, et al. N-terminal deletion in a desmosomal cadherin causes the autosomal dominant skin disease striate palmoplantar keratoderma. Hum Mol Genet. 1999;8:971–976. [PubMed]
15. Allen E, Yu QC, Fuchs E. Mice expressing a mutant desmosomal cadherin exhibit abnormalities in desmosomes, proliferation, and epidermal differentiation. J Cell Biol. 1996;133:1367–1382. [PMC free article] [PubMed]
16. Montagutelli X, Lalouette A, Boulouis HJ, Guenet JL, Sundberg JP. Vesicle formation and follicular root sheath separation in mice homozygous for deleterious alleles at the balding (bal) locus. J Invest Dermatol. 1997;109:324–328. [PubMed]
17. Koch PJ, et al. Targeted disruption of the pemphigus vulgaris antigen (desmoglein 3) gene in mice causes loss of keratinocyte cell adhesion with a phenotype similar to pemphigus vulgaris. J Cell Biol. 1997;137:1091–1102. [PMC free article] [PubMed]
18. Lenox JM, et al. Postnatal lethality of P-Cadherin/Desmoglein 3 double knockout mice: demonstration of a cooperative effect of these cell adhesion molecules in tissue homeostasis of stratified squamous epithelia. J Invest Dermatol. 2000;114:948–952. [PubMed]
19. Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley JR. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest. 1992;90:919–926. [PMC free article] [PubMed]
20. Karpati S, Amagai M, Prussick R, Cehrs K, Stanley JR. Pemphigus vulgaris antigen, a desmoglein type of cadherin, is localized within keratinocyte desmosomes. J Cell Biol. 1993;122:409–415. [PMC free article] [PubMed]
21. Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest. 1994;94:59–67. [PMC free article] [PubMed]
22. Amagai M, Hashimoto T, Green KJ, Shimizu N, Nishikawa T. Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. J Invest Dermatol. 1995;104:895–901. [PubMed]
23. Amagai M, Nishikawa T, Nousari HC, Anhalt GJ, Hashimoto T. Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. J Clin Invest. 1998;102:775–782. [PMC free article] [PubMed]
24. Nguyen VT, Ndoye A, Grando SA. Novel human α9 acetylcholine receptor regulating keratinocyte adhesion is targeted by pemphigus vulgaris autoimmunity. Am J Pathol. 2000;157:1377–1391. [PubMed]
25. Labib RS, Rock B, Robledo MA, Anhalt GJ. The calcium-sensitive epitope of pemphigus foliaceus antigen is present on a murine tryptic fragment and constitutes a major antigenic region for human autoantibodies. J Invest Dermatol. 1991;96:144–147. [PubMed]
26. Eyre RW, Stanley JR. Identification of pemphigus vulgaris antigen extracted from normal human epidermis and comparison with pemphigus foliaceus antigen. J Clin Invest. 1988;81:807–812. [PMC free article] [PubMed]
27. Hashimoto T, Ogawa MM, Konohana A, Nishikawa T. Detection of pemphigus vulgaris and pemphigus foliaceus antigens by immunoblot analysis using different antigen sources. J Invest Dermatol. 1990;94:327–331. [PubMed]
28. Hashimoto T, Konohana A, Nishikawa T. Immunoblot assay as an aid to the diagnoses of unclassified cases of pemphigus. Arch Dermatol. 1991;127:843–847. [PubMed]
29. Dmochowski M, Hashimoto T, Nishikawa T. The analysis of IgG subclasses of anti-intercellular antibodies in pemphigus by an immunoblot technique. Arch Dermatol Res. 1992;284:309–311. [PubMed]
30. Emery DJ, et al. Pemphigus foliaceus and pemphigus vulgaris autoantibodies react with the extracellular domain of desmoglein-1. J Invest Dermatol. 1995;104:323–328. [PubMed]
31. Ding X, et al. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol. 1997;109:592–596. [PubMed]
32. Mahoney MG, et al. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest. 1999;103:461–468. [PMC free article] [PubMed]
33. Beutner EH, Chorzelski TP, Jablonska S. Immunofluorescence tests. Clinical significance of sera and skin in bullous diseases. Int J Dermatol. 1985;24:405–421. [PubMed]
34. Grando SA, Dahl MV. Activation of keratinocyte muscarinic acetylcholine receptors reverses pemphigus acantholysis. J Eur Acad Dermatol Venereol. 1993;2:72–86.
35. Nguyen VT, Ndoye A, Grando SA. Pemphigus vulgaris antibody identifies pemphaxin: a novel keratinocyte annexin-like molecule binding acetylcholine. J Biol Chem. 2000;275:29466–29476. [PubMed]
36. Olague-Alcala M, Giudice GJ, Diaz LA. Pemphigus foliaceus sera recognize an N-terminal fragment of bovine desmoglein 1. J Invest Dermatol. 1994;102:882–885. [PubMed]
37. Amagai M, Tsunoda K, Zillikens D, Nagai T, Nishikawa T. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol. 1999;40:167–170. [PubMed]
38. Lenz P, Amagai M, Volc-Platzer B, Stingl G, Kirnbauer R. Desmoglein 3-ELISA: a pemphigus vulgaris-specific diagnostic tool. Arch Dermatol. 1999;135:143–148. [PubMed]
39. Amagai M, et al. Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol. 1999;140:351–357. [PubMed]
40. Schiltz JR, Michel B. Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. J Invest Dermatol. 1976;67:254–260. [PubMed]
41. Swanson DL, Dahl MV. Methylprednisolone inhibits pemphigus acantholysis in skin cultures. J Invest Dermatol. 1983;81:258–260. [PubMed]
42. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med. 1982;306:1189–1196. [PubMed]
43. Nguyen V, Kadunce DP, Hendrix JD, Gammon WR, Zone JJ. Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses. J Invest Dermatol. 1993;100:349–355. [PubMed]
44. Ding X, Diaz LA, Fairley JA, Guidice GJ, Liu Z. The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic. J Invest Dermatol. 1999;112:739–743. [PubMed]
45. Wilgram GF, Caulfield JB, Lever WF. An electron microscopic study of acantholysis in pemphigus vulgaris. J Invest Dermatol. 1961;36:373–382. [PubMed]
46. Cohen, L.M., Skopicki, D.K., Harrist, T.J., and Clark, W.H., Jr. 1997. Noninfectious vesicobullous and vesicopustular diseases. In Lever’s histopathology of the skin. D. Elder, R. Elenitas, C. Jaworsky, and B.J. Johnson, editors. Lippincott-Raven. Philadelphia, Pennsylvania, USA. 209–252.
47. Udey MC, Stanley JR. Pemphigus: diseases of antidesmosomal autoimmunity. JAMA. 1999;282:572–576. [PubMed]
48. Mahoney MG, et al. Explanation for localization of blisters in pemphigus patients. J Invest Dermatol. 1998;110:499. (Abstr.)
49. Bellone AG, Leone V. Ricerche sull’influenza esercitata da sieri di soggetti sani o affetti da pemfigo su pelle umana normale e pemfigosa coltivata “in vitro” G Ital Dermatol Minerva Dermatol. 1956;97:97–109. [PubMed]
50. Farb RM, Dykes R, Lazarus GS. Anti-epidermal-cell-surface pemphigus antibody detaches viable epidermal cells from culture plates by activation of proteinase. Proc Natl Acad Sci USA. 1978;75:459–463. [PubMed]
51. Patel HP, Diaz LA, Anhalt GJ, Labib RS, Takahashi Y. Demonstration of pemphigus antibodies on the cell surface of murine epidermal cell monolayers and their internalization. J Invest Dermatol. 1984;83:409–415. [PubMed]
52. Beutner E, Jordon R. Demonstration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescent staining. Proc Soc Exp Biol Med. 1964;117:505–510. [PubMed]
53. Johnston RF, Pickett SC, Barker DL. Autoradiography using storage phosphor technology. Electrophoresis. 1990;11:355–360. [PubMed]
54. Zouboulis CC, Tavakkol A. Storage phosphor imaging technique improves the accuracy of RNA quantitation using 32P-labeled cDNA probes. Biotechniques. 1994;16:290–292, 294. [PubMed]
55. Abreu-Velez AM, et al. Characterization of a 45 kD epidermal tryptic peptide recognized by pemphigus foliaceus sera. J Invest Dermatol. 1997;108:541. (Abstr.)
56. Ishii K, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol. 1997;159:2010–2017. [PubMed]
57. Kitajima Y, Aoyama Y, Seishima M. Transmembrane signaling for adhesive regulation of desmosomes and hemidesmosomes, and for cell-cell detachment induced by pemphigus IgG in cultured keratinocytes: involvement of protein kinase C. J Invest Dermatol Symp Proc. 1999;4:137–144. [PubMed]
58. Aoyama Y, Kitajima Y. Pemphigus vulgaris-IgG causes a rapid depletion of desmoglein 3 (Dsg3) from the triton X-100 soluble pools, leading to the formation of Dsg3-depleted desmosomes in a human squamous carcinoma cell line, DJM-1 cells. J Invest Dermatol. 1999;112:67–71. [PubMed]
59. Aoyama Y, Owada MK, Kitajima Y. A pathogenic autoantibody, pemphigus vulgaris-IgG, induces phosphorylation of desmoglein 3, and its dissociation from plakoglobin in cultured keratinocytes. Eur J Immunol. 1999;29:2233–2240. [PubMed]
60. Xue W. Pemphigus vulgaris IgG regulates expression of urokinase receptor and junctional proteins that may contribute to acantholysis. J Am Acad Dermatol. 1999;41:462–463. [PubMed]
61. Benz J, Hofmann A. Annexins: from structure to function. Biol Chem. 1997;378:177–183. [PubMed]
62. Grando SA. Biological functions of keratinocyte cholinergic receptors. J Invest Dermatol Symp Proc. 1997;2:41–48. [PubMed]
63. Vasioukhin V, Bauer C, Yin M, Fuchs E. Directed actin polymerization is the driving force for epithelial cell-cell adhesion. Cell. 2000;100:209–219. [PubMed]
64. Hu Z, et al. Mutations in ATP2C1, encoding a calcium pump, cause Hailey-Hailey disease. Nat Genet. 2000;24:61–65. [PubMed]
65. Sakuntabhai A, et al. Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease. Nat Genet. 1999;21:271–277. [PubMed]
66. Grando SA. Autoimmunity to keratinocyte acetylcholine receptors in pemphigus. Dermatology (Basel) 2000;201:290–295. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation